Market Newsdesk

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a technology company in the defense, national security and global markets, announced today that it has received an approximate $30 million Sole Source Air Defense System Hardware Production award.  Kratos is an industry leading designer, engineer and manufacturer of military grade hardware, at quantity, in support of United States air defense, hypersonic, propulsion, high-performance jet drones and other mission critical National Security related systems.  Work under this production award will be performed at a secure Kratos manufacturing facility.   Due to competitive, security related and other considerations, no additional information will be provided related to this award.

Eric DeMarco, President and CEO of Kratos, said, “Kratos is a recognized industry leader in designing, engineering and manufacturing military grade hardware for weapon systems—systems that have to work every time for our warfighters, partners and customers.  Kratos’ C5ISR business unit is currently under contract and in large scale production on multiple hypersonic, missile, radar, and air defense related systems, including this program award we announced today. Our entire Company is proud to have been selected to produce and provide this critical air defense system hardware for this United States National Security customer.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:

Claire Burghoff
[email protected]

Investor Information:

877-934-4687
[email protected]

WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.

“Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is approaching important inflection points this year with interim dose expansion data from the WTX-124 Phase 1/1b clinical trial expected to guide discussions with regulators on potential registrational pathways, and our PREDATOR platform continuing to develop novel molecules for oncology, immunology and additional therapeutic modalities.”

Mr. Bloom joins Werewolf from Vincerx Pharma, Inc., where he served as Chief Business Officer. During his time at Vincerx as a member of the executive leadership team focused on business development, commercial assessment, and corporate strategy, Mr. Bloom led a program and platform valuation project and worked with the executive team on multiple transaction initiatives to help stabilize the company.   Previously, he worked at several biotechnology companies including Ziopharm Oncology, Inc., Verastem Oncology, and Vavotar Life Sciences LLC, where he led multiple business development transactions. Mr. Bloom also held senior roles at Eli Lilly and Company earlier in his career where he led sales and marketing, patient advocacy, and corporate affairs functions.

“Werewolf is positioning itself to change the way cancer is treated through its novel immunotherapy technology designed to attack the tumor while minimizing patient side effects,” said Mr. Bloom. “Werewolf’s lead program WTX-124 has demonstrated durable confirmed responses in patients with cancer, and Werewolf has continued to develop a deep and diverse pipeline using its PREDATOR technology. I am thrilled to join this experienced team and look forward to working with Werewolf to advance its products.”

Mr. Bloom graduated from Northeastern University School of Pharmacy and has been an American Cancer Society Road to Recovery driver since 2008. Mr. Bloom is currently Chair of the Board of Directors of the CLL Society, a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma community through patient education, advocacy, support, and research.

In connection with Mr. Bloom’s appointment, Werewolf’s board of directors approved a stock option grant to Mr. Bloom as an inducement material to his entering into employment with Werewolf in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 201,720 shares of Werewolf common stock at an exercise price equal to the closing price of the Werewolf common stock on May 1, 2025, the effective date of grant.  The stock option has a ten-year term and vests as to 25% on the first anniversary of the effective date of Mr. Bloom’s employment and the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service by Mr. Bloom to Werewolf or any of its subsidiaries through each applicable vesting date.

About Werewolf Therapeutics:

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR^® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management; the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “positioning itself to,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” “working to,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

WEREWOLF^®, the WEREWOLF logo, PREDATOR^®, INDUKINE^™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Investor Contact

Dan Ferry
LifeSci Advisors
617.430.7576
[email protected]

Media Contact:

Amanda Sellers
Deerfield Group
301.332.5574
[email protected]

Company Contact:

Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
[email protected]

MCLEAN, Va., April 17, 2025 (GLOBE NEWSWIRE) — Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, reports financial results for full year ended December 31, 2024, and provides a corporate update highlighting a year of strategic execution, operational discipline, and solid financial performance.

Cycurion is poised for a strong 2025, driven by a strategic overhaul focused on sustainable growth and innovation. Over the past year, the company streamlined operations, significantly cutting General and Administrative (G&A) expenses while boosting gross profit for greater financial strength. Cycurion invested heavily in AI-driven technology, sharpening its competitive edge. By pivoting away from low-margin clients to high-value opportunities, the Company has built a robust framework for organic growth while paving the way for expansion, entering 2025 with clear momentum and vision.

Financial Highlights

• Revenues of $17.8 million
• SG&A expenses reduced by 47.5%, demonstrating operational efficiency and tighter strategic focus
• Adjusted EBITDA of $2.3 million, up 58.9% year-over-year with an expanded margin of 12.9% vs $1.4 million (7.4% margin) in FY2023, reflecting strong cost management and scalable operations 
• Net income of $1.2 million, a significant turnaround from a net loss of $2.1 million in FY2023 — marking Cycurion’s first full year of net profitability 
• Earnings per share improvement to $0.07 basic and $0.01 fully diluted, versus $(0.14) in both categories in FY2023 
• Free Cash Flow improvement to $(1.8) million from $(2.5) million despite growth investments in personnel and platform development 

2024 & YTD 2025 Strategic, Technological and Corporate Milestones

Cycurion significantly expanded its next-generation product and services portfolio, further solidifying its position as a trusted partner in advanced cybersecurity solutions: 

• Listed & Began Trading on Nasdaq: Completed merger with Western Acquisition Ventures in February 2025
• U.S. Launch of AI-driven SaaS ARx Cybersecurity Platform: New high margin, AI-driven cybersecurity solution expands Company’s reach following strong initial reception in the government and public sectors in March 2025
• Launched Cyber Shield Managed Security Services Platform (MSSP) Launch: Includes SOC as Service, External Attack Surface Management, Web Application Firewall and Virtual CISO Support & Consulting
• Expanded Partnership with Journal Technologies: Secured $22 million multi-year contract with State Police Agency
• Strengthened Board of Directors Appointing Two Highly Accomplished IT Professionals: Kevin O’Brien and Reginald Bailey bring a combined 55 years of IT, Big Data and AI industry, entrepreneurial and C-suite experience to Cycurion

Management Commentary


Kevin Kelly, Cycurion CEO, stated, “We are pleased with Cycurion’s 2024 performance, especially with our ability to produce meaningful adjusted EBITDA growth coupled with positive net income of $1.2 million. This is particularly significant given an 8.2% revenue decrease due to non-recurring, one-time equipment purchases in 2023. Our strong foundation positions us for continued growth with tremendous momentum with both current and new clients, which will become evident over the next 3-6 months underpinning our belief of a promising 2025.”

About Cycurion

Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.

Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Investor Contact:

CORE IR
[email protected]

Media Contact:

Phone: (703) 555-0123
Email: [email protected]

Non-GAAP Financial Measures

Statements in this release include financial information presented in accordance with accounting principles generally accepted in the United States (“GAAP”) and also include non-GAAP financial measures that are provided as additional information to enhance the overall understanding of the Company’s current financial performance and not as an alternative to the consolidated interim financial statements presented in accordance with GAAP. Management uses these non-GAAP measures (earnings before interest, taxes, depreciation, and amortization (“EBITDA”), Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow) to evaluate the Company’s financial performance. These terms might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures reported by other companies. The financial information tables that accompany this press release include reconciliations of net income to non-GAAP financial measures.

EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin provide a measure of the Company’s operating results in a manner that is focused on the performance of the Company’s core business on an ongoing basis, by removing the effects of non-operating and certain non-cash expenses. These non-operating and non-cash items are specifically identified in the reconciliations of GAAP measures to Non-GAAP measures that accompany this release.

Free Cash Flow provides useful information to investors about the amount of cash generated by the business that can be used for strategic opportunities and is computed as Cash Flows from Operating Activities less both the Purchase of Property and Equipment & Purchase of Intangible Assets.

CYCURION, INC. AND ITS SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
		December 31,				December 31,
		2024				2023
Assets
Current assets
Cash		$	38,742			$	607,869
Restricted cash			2,048				–
Accounts receivable, net			10,353,708				7,093,371
Other receivables			434,391				455,979
Due from sponsor			106,421				–
Note receivable – WAVS			–				200,000
Prepaid expenses and other current assets			99,463				56,015
Total current assets		$	11,034,773			$	8,413,234
Non-current assets
Deposit for acquisition target			2,000,000				2,000,000
Fixed assets, net			4,175,169				3,779,310
Intangible assets, net			25,000				–
Security deposits			10,351				10,351
Goodwill			6,592,304				6,592,304
Investments held in Trust Account			1,834,540				–
Total non-current assets			14,637,364				12,381,965
Total Assets		$	25,672,137			$	20,795,199
Liabilities, Mezzanine and Stockholders’ Equity
Current liabilities
Bank loan-revolving credit line			3,249,067				2,996,753
Bank loan-current portion			774,095				742,141
Loans payable			408,516				408,516
Subordinated convertible promissory notes			3,333,335				3,333,335
Promissory notes			2,624,111				1,561,111
Loans payable – related parties			(325,600	)			587,400
Accounts payable			3,552,674				2,066,760
Due to Trust Account			106,421				–
Accrued liabilities			3,601,242				2,158,255
Income Tax Payable			12,500				–
Franchise tax payable			13,200				–
Excise tax payable			1,157,161				–
Advance from Sponsor			330,000				–
Deferred revenue			189,150				253,902
Total current liabilities			19,025,872				14,108,173
Long-term loan payable			146,798				146,798
Series A convertible preferred stock ($0.001 par value, 500,000 shares designated, 345,528 issued and outstanding)			1,294,117				1,294,117
Total non-current liabilities			1,440,915				1,440,915
Total Liabilities		$	20,466,787			$	15,549,088
Commitments and contingencies
Mezzanine Equity
Common stock subject to possible redemption, $0.0001 par value, 173,879 shares at redemption value of approximately $11.03 per share at December 31, 2024			1,917,309				–
Stockholders’ Equity
Preferred stock ($0.0001 par value, 20,000,000 shares authorized)
Series B convertible preferred stock ($1.00 stated value, 3,000 shares designated, 3,000 and 2,000 issued and outstanding, respectively)			–				–
Series C convertible preferred stock ($82.46 stated value, 5,000 shares designated, 4,851 issued and outstanding)			–				–
Common stock ($0.0001 par value, 70,000,000 shares authorized, 10,592,607 and 7,341,607 shares issued and outstanding)			1,059				1,028
Additional paid in capital			6,670,060				9,678,045
Accumulated deficit			(3,383,078	)			(4,432,962	)
Total Stockholders’ Equity			3,288,041				5,246,111
Total Liabilities and Stockholders’ Equity		$	25,672,137			$	20,795,199

CYCURION, INC. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
		Years ended
		December 31,
		2024				2023
Net revenues		$	17,582,335			$	19,350,208
Cost of revenues			14,136,742				16,707,148
Gross profit			3,445,593				2,643,060
Operating expenses:
Selling, general and administrative expenses			1,215,763				2,316,649
Operating income (loss)			2,229,830				326,411
Other income (expenses):
Interest income			20,211				–
Interest expense			(1,202,936	)			(2,074,089	)
Other income			28,020				–
Other expense			(25,241	)			(345,548	)
Other income (expenses)			(1,179,946	)			(2,419,637	)
Profit (loss) before income taxes			1,049,884				(2,093,226	)
Provision before income taxes			–				3,787
Net income (loss)		$	1,049,884			$	(2,097,013	)
Comprehensive income (loss)		$	1,049,884			$	(2,097,013	)
Net income (loss) per common share
Basic income (loss) per common share		$	0.07			$	(0.14	)
Diluted loss per common share		$	0.01			$	(0.14	)
Basic and diluted weighted average common shares outstanding			14,968,215				14,782,442
Diluted weighted average common shares outstanding			89,495,790				14,782,442

CYCURION, INC. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
		Years ended
		December 31,
		2024				2023
Cash flows from operating activities
Net income (loss)		$	1,049,884			$	(2,097,013	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock based compensation			10,000				327,499
Amortization of debt discount			–				1,094,131
Depreciation of fixed assets			27,142				25,822
Changes in operating assets and liabilities:
Change of right of use asset and lease liabilities			–				(7,810	)
Accounts and other receivables			(3,238,749	)			(4,636,805	)
Advance and prepayments to suppliers			(43,448	)			(40,917	)
Accounts and other payables			908,854				3,105,223
Accrued interest			(20,211	)			–
Deferred revenue			(64,752	)			242,099
Net cash used in operating activities			(1,371,280	)			(1,987,771	)
Cash flows from investing activities
Acquisition of WAVS			2,048				–
Promissory note issued by WAVS			(439,114	)			(200,000	)
Purchase of plant and equipment			(423,001	)			(506,707	)
Purchase of Intangible asset			(25,000	)			–
Net cash used in investing activities			(885,067	)			(706,707	)
Cash flows from financing activities
Proceeds from private placement			1,000,000				2,000,000
Net proceeds from line of credit			252,314				5,346
Proceeds from all bank borrowings			–				–
Repayment of all bank borrowings			31,954				(193,305	)
Proceeds from loans payable			–				339,500
Repayments of loans payable			–				(29,379	)
Proceeds from notes payable by WAVS			255,000				–
Proceeds from notes payable			205,000				550,000
Proceeds from notes payable – related parties			15,000				534,000
Repayments of notes payable – related parties			–				–
Net cash provided by financing activities			1,759,268				3,206,162
Net change in cash and restricted cash			(497,079	)			511,684
Cash –beginning of period			607,869				96,185
Cash–end of period		$	110,790			$	607,869
Restricted cash – end of period		$	2,048			$	–
Cash – end of period		$	38,742			$	–
Supplementary cash flow information:
Interest paid		$	–			$	501,337
Income taxes paid		$	–			$	–

CYCURION, INC. AND ITS SUBSIDIARIES RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Unaudited)
		Years ended
		December 31,
			2024				2023
Net income (loss)		$	1,049,884			$	(2,097,013	)
Provision for income taxes			–				3,787
Interest expense			1,202,936				2,074,089
Interest income			(20,211	)			–
Amortization of debt discount			–				1,094,131
Depreciation of fixed assets			27,142				25,822
EBITDA (non-GAAP measure)		$	2,259,751			$	1,100,816
Stock compensation expense			10,000				327,499
Adjusted EBITDA (non-GAAP measure)		$	2,269,751			$	1,428,315

SALT LAKE CITY, April 17, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2025 operating results on Wednesday, May 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

Conference Call Details

The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID “HCATQ125.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst’s offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.

Health Catalyst Investor Relations Contact:

Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
[email protected]

Health Catalyst Media Contact:

‍Kathryn Mykleseth
Director of Public Relations and Communications ‍
[email protected]

CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR.

Poster presentation details:

Title: Elraglusib, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer
Session Title: Phase II Clinical Trials 2
Session Date and Time: April 29, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 50
Abstract Presentation Number: CT212

“Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid Cystic Carcinoma (ACC) population with nuclear GSK-3β overexpression given this difficult to treat and rare cancer type”, said Dr. Glenn Hanna, Director of the Center for Cancer Therapeutic Innovation (CCTI), the early drug development program at Dana Farber Cancer Institute, who led the team conducting this clinical study.

Separately, an independent research group led by Dr. Wafik S El-Deiry from Legorreta Cancer Center at Brown University will present a poster demonstrating the synergistic effects of elraglusib in combination with ONC206 or ONC212, investigational compounds from Jazz Pharmaceuticals plc.

Poster presentation details:

Title: Elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor in combination with imipridones for treatment of solid cancer
Session Title: Drug Combination Strategies for Cancer Treatment
Session Date and Time: April 28, 2025, 9:00 AM – 12:00 PM
Location: Poster Section Poster Section 19
Abstract Presentation Number: 1693

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; preliminary and unpublished data may be subject to change following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; our reliance on third parties to conduct our non-clinical studies and our clinical trials and that third party studies reflect parameters and circumstances that are not established by us; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
[email protected]

Juve Stabia recorded its highest home attendance of the season during the recent derby fixture against Salernitana on April 5

Dublin, Ireland and Milan, Italy, April 17, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings” or the “Company”) (Nasdaq: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men’s and women’s football clubs through a multi-club ownership (“MCO”) strategy, announced that its Serie B portfolio club, S.S. Juve Stabia S.r.l., “The Second Team of Naples,” recorded its highest home attendance of the season during the recent derby fixture against Salernitana on April 5—an important moment in the club’s broader commercial growth strategy.

A crowd of 7,000 fans filled Stadio Romeo Menti, just 100 seats shy of a full sellout (stadium capacity: 7,100), delivering not only a vibrant atmosphere but a meaningful uplift in matchday revenue. The club has identified stadium monetization as a key priority and is undergoing its season ticket campaign for the 2025–26 season, with a focus on increasing recurring revenue and fan engagement.

“The turnout wasn’t just a show of passion—it was a tangible step forward in our matchday revenue strategy,” said Daniel McClory, Executive Chairman of Brera Holdings. “Our goal is to build a commercially sustainable club, and that starts with maximizing our stadium potential and deepening the connection with our supporters.”

Juve Stabia currently ranks 5th in Serie B, with strong on-field momentum and growing off-field value. According to Transfermarkt, the club recently achieved the highest squad value increase in the league, rising 36.9% to €16.13 million since mid-March. The club’s commercial strategy is designed to complement its sporting ambition, with investments in infrastructure, ticketing, and fan experience all supporting long-term growth.

The club’s home ground, Stadio Romeo Menti, has long been a symbol of identity for the city of Castellammare di Stabia. As the club ramps up initiatives to improve attendance and yield, the match highlighted the untapped potential of Juve Stabia’s local market.

“Matchday revenues are one of the most direct and scalable levers for growth at this level of football,” said McClory. “We’re encouraged by the traction and remain focused on building a strong commercial foundation for Juve Stabia’s continued ascent.”

ABOUT BRERA HOLDINGS PLC

Brera Holdings PLC (Nasdaq: BREA) is dedicated to expanding its social impact football business by developing a global portfolio of emerging football and sports clubs. Building on the legacy of Brera FC, which it acquired in 2022, the Company aims to create opportunities for tournament prizes, sponsorships, and professional consulting services. Brera FC, recognized as “The Third Team of Milan,” has been crafting an alternative football legacy since its founding in 2000. The club also organizes the FENIX Trophy, a nonprofessional pan-European tournament acknowledged by UEFA. This tournament, which has been referred to as “the Champions League for Amateurs” by BBC Sport, has garnered significant media coverage, including from ESPN.

In its efforts to broaden its reach, Brera expanded into Africa in March 2023 by establishing Brera Tchumene FC in Mozambique, which quickly rose to the First Division after winning its post-season tournament. In April 2023, the Company acquired a 90% stake in the North Macedonian first-division team Fudbalski Klub Akademija Pandev, now known as Brera Strumica FC. Additionally, in June 2023, Brera made a strategic investment in Manchester United PLC, realizing a 74% gain. The Company has further diversified its portfolio by acquiring a majority stake in UYBA Volley, an Italian women’s professional volleyball team, in July 2023, assuming control of Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team, which became Brera Ilch FC, in September 2023, and establishing a joint stock company for the North Macedonian women’s football club Tiverija Strumica, now known as Brera Tiverija FC, a wholly-owned subsidiary of Brera Strumica FC, in June 2024.

On December 31, 2024, Brera signed of an agreement to acquire majority ownership of SS Juve Stabia srl, an Italian Serie B football club known as “The Second Team of Naples,” which will be conducted in a multi-step process, and marks a significant expansion of the Company’s MCO model. As of February 12, 2025, Brera holds a 38.46% equity ownership interest in Juve Stabia. With a strategic emphasis on bottom-up value creation, innovation-driven growth, and socially impactful outcomes, Brera Holdings has established itself as a forward-thinking leader in the global sports industry. For more information, visit www.breraholdings.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, the popularity and/or competitive success of the Company’s acquired football and other sports teams, the Company’s ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company’s ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Company Contact Information:

Dan McClory, Executive Chairman, Brera Holdings PLC
Email: [email protected]

Attachment

• Juve Stabia recorded its highest home attendance of the season during the recent derby fixture against Salernitana on April 5

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30^th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until May 7, 2025, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 3746692. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR

Yvonne Briggs, 310-691-7100
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]

DENVER, April 17, 2025 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), the nation’s largest provider of the Program of All-inclusive Care for the Elderly (PACE) based on participants served, has engaged staff, nationwide, to reinforce the critical need for this successful senior care program. InnovAge teams are meeting with lawmakers nationwide and building positive support among decision makers about the PACE program, known as healthcare’s “best kept secret.”

Currently available in 33 states and the District of Columbia–predominantly through a combination of Medicare and Medicaid funding–PACE provides intimately collaborative and highly coordinated care that addresses all aspects of health for seniors who might otherwise turn to nursing homes. Enrolled seniors receive in-home care, transportation, primary and specialty care, meals and nutrition, physical and occupational therapy, dental, hearing, and vision services, as well as have a place to socialize, exercise, and partake in activities and outings.

“This model is unique because PACE organizations are providers, payors, and care delivery systems, all rolled into one,” says InnovAge CEO Patrick Blair, “that helps to improve outcomes and participant satisfaction while also providing cost savings to our federal and state partners.”

“Federal or state policy makers who want to stand by seniors and make sure senior health needs are being met need to know that PACE is the time-tested, cost-effective, high-quality health care program,” says InnovAge SVP of External Affairs John Koehn.

“PACE is a model of care that is being increasingly recognized for its outcomes, cost-effectiveness, and the high quality of life it provides the seniors enrolled in the program,” said National PACE Association President and CEO Shawn Bloom. “As a result, we are seeing the highest rate of PACE growth in our history as more states and providers look to create and expand PACE to serve more seniors with long-term care needs.”

The Federal Department of Health and Human Services concluded in its 2021 report that PACE “stands out from our analysis as a consistently ‘high performer.’” And in 2022, research by the Bipartisan Policy Center found that PACE participants experience 44% fewer preventable hospitalizations compared to dually eligible Medicaid nursing home residents. The report also found that PACE saves state governments $6,000 per person annually of Medicaid per capita spending, on average (through reduced Medicaid payments), compared to nursing homes while providing high quality comprehensive care.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of December 31, 2024, InnovAge served approximately 7,480 participants across 20 centers in six states. https://www.innovage.com

Lara Hazenfield	John Eddy
InnovAge Public Relations Manager	Goldin Solutions for InnovAge
[email protected]	[email protected]

SOMERSET, N.J., April 17, 2025 (GLOBE NEWSWIRE) —
CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, will release its financial results for the first quarter ended March 31, 2025 before the market opens on Tuesday, May 6, 2025. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time.

The live webcast of the conference call and related presentation slides can be accessed at ir.carecloud.com/events. An audio-only option is available by dialing 201-389-0920 and referencing “CareCloud First Quarter 2025 Results Conference Call.” Investors who opt for audio-only will need to download the related slides at ir.carecloud.com/events.

A replay of the conference call and related presentation slides will be available approximately three hours after conclusion of the call at the same link. An audio-only option can also be accessed by dialing 412-317-6671 and providing the access code 13753440.

About CareCloud

CareCloud (Nasdaq: CCLD, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of AI and technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at carecloud.com.

Follow CareCloud on LinkedIn, X and Facebook.

For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.

SOURCE CareCloud

Company Contact:

Norman Roth
Interim Chief Financial Officer and Corporate Controller
CareCloud, Inc.
[email protected]

Investor Contact:

Stephen Snyder
Co-Chief Executive Officer
CareCloud, Inc.
[email protected]

CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals.

“We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC^® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “His extensive expertise in clinical development and regulatory strategy, combined with a passion for innovation and patient-focused outcomes, will be instrumental as we advance our therapies to address critical unmet needs in rare genetic disorders and position the company for long-term value creation.”

Most recently, Dr. Storgard served as CMO at ADARx Pharmaceuticals, where he transitioned the organization from research to development-stage operations, overseeing the advancement of multiple clinical programs, including preparations for the company’s first global Phase 3 program. Prior to that, he held the CMO position at Heron Therapeutics where he oversaw teams that secured U.S. and European approvals for several products in oncology and acute care. He also served as CMO at Fate Therapeutics, where he filed the first investigational new drug application for an iPSC-derived, off-the-shelf, natural killer cell product for oncology. Previously, Dr. Storgard served as Vice President of Clinical Research and Development at Ardea Biosciences (an AstraZeneca Company), where he successfully led the global clinical program for lesinurad, culminating in regulatory approvals in multiple global markets, including the United States and Europe. His career also includes clinical development roles at Biogen Idec and Amgen, as well as clinical and academic appointments at the Mayo Clinic, Scripps Mercy Hospital and The Scripps Research Institute. Dr. Storgard received his M.D. and BSc degrees from the University of Saskatchewan and is board-certified in Rheumatology and Internal Medicine.

“I am excited to join Design and be part of a passionate team dedicated to transforming the lives of patients with severe genetic diseases,” said Dr. Storgard. “The company’s innovative approach with GeneTAC^® small molecules represents a compelling opportunity to deliver meaningful clinical advancements across a range of monogenetic disorders, starting with DT-216P2 for Friedreich ataxia. I look forward to applying my experience to further drive clinical and regulatory execution and to realize the full potential of Design’s pipeline.”

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC^® gene targeted chimera small molecules. The company’s GeneTAC^® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC^® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to Dr. Storgard’s potential contribution to the company; Design’s ability to advance its pipeline of GeneTAC^® small molecules and create long-term value; and the capabilities and potential advantages of Design’s pipeline of GeneTAC^® small molecules. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “designed to,” “anticipates,” “capable of,” “on track to,” “plans to,” “expects,” “estimate,” “intends,” “will,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Design’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the acceptance of INDs by the FDA or similar applications by foreign regulatory agencies for the conduct of planned clinical trials of our product candidates and our proposed design of future clinical trials; nonclinical development activities and results of nonclinical studies; conducting a clinical trial and patient enrollment, which are affected by many factors, and any difficulties or delays encountered with such clinical trial or patient enrollment may delay or otherwise adversely affect Design’s clinical development plans; the process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company; undesirable side effects or other undesirable properties, which could cause Design or regulatory authorities to suspend or discontinue clinical trials and thereby delay or prevent Design’s product candidates’ development or regulatory approval; Design’s ability to develop, initiate or complete nonclinical studies and clinical trials for its product candidates; whether promising early research or clinical trials will demonstrate safety and/or efficacy in later nonclinical studies or clinical trials; changes in Design’s plans to develop its product candidates; reliance on third parties to successfully conduct clinical trials and nonclinical studies; competitive products, which may make any products we develop or seek to develop obsolete or noncompetitive; Design’s reliance on key third parties, including contract manufacturers and contract research organizations; Design’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Design’s ability to obtain and maintain intellectual property protection for its product candidates; Design’s ability to recruit and retain key scientific or management personnel; and market conditions. For a more detailed discussion of these and other factors, please refer to Design’s filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of Design’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 10, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Design undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Contact:

Renee Leck
THRUST Strategic Communications
[email protected]